Annotated Bibliography Graphic Organizer

Neonatal Junctional Epidermolysis Bullosa: Treatment Conundrums and Ethical Decision Making.

Name: Betsy Frazier

Source #3 Bibliography Yang, Catherine, Daniela Kroshinksy, and Brian Cummings.

MLA "Neonatal Junctional Epidermolysis Bullosa: Treatment
Conundrums And Ethical Decision Making." American Journal
Of Clinical Dermatology 15.5 (2014): 445. Advanced
Placement Source. Web. 16 Feb. 2017.

Annotation: This academic journal discusses the treatments of EB that have

(Describe ALL info. that and have not been used. In addition, it calls into questions the
ethics of the disease, as no logical treatments and procedures
might be important for
have been conducted to prolong the lives of children with EB.
your paper. Explain to
The article highlights the fact that the average life span of 5
the reader and/or months and at most, 3 years. This means that they only have a
summarize what might short time frame to experiment with procedures, but it could
be found in this source) expand the lives of many sufferers if they give it a chance.

Potential Quotes: Junctional epidermolysis bullosa has an

(Are there any significant
quotes you can use or
paraphrase from this
source?)
extremely poor prognosis, with a mean age of death at
5 months old and most dead before age 3 years. (Page
1)
Invasive treatments such as gastrostomy tube
placements, intubations, and central line placements
have not been shown in cohort studies to prolong life,
thus raising the ethical dialectic of providing the
maximum possible level of medical care balanced with
the degree of suffering these infants endure. (Page 1)
The incidence of JEB-gen sev is estimated to
be 0.44.0 per million live births (Page 1)
Common causes of death were failure to thrive,
respiratory failure, and sepsis (Page 2)

Assessment: This source is credible because it was written by medical

(Analyze and explain doctors in dermatology, which reveals that they have seen
patients with this disease and the aim is to treat it effectively. In
why this source is
addition, this academic journal is written for an audience that is
credible)
interested in this topic because it is written for the American
Journal of Clinical Dermatology.

Reflection (not the This source is very useful in describing the ethics of treatments
summary): that have not been used before, but make logical sense. The
authors bring up the point on how their main mission is to
(How will you potentially
use it?) cause no harm and to save lives, but they are not doing so by
not experimenting with procedures that could potentially lead to
a cure of Epidermolysis Bullosa or lessen the severity of the
symptoms that come along with the disease. I will use this
source as a way of discussing innovations that can be make in
the treatment of Epidermolysis Bullosa. In addition, I will
discuss how each of these procedures might be useful in
finding a cure and adding onto what the authors say by
explaining my point of view on why these treatments have not
been conducted.

Source/ bibliography:
Yang, Catherine, Daniela Kroshinksy, and Brian Cummings. "Neonatal Junctional Epidermolysis
Bullosa: Treatment Conundrums And Ethical Decision Making." American Journal Of Clinical
Dermatology 15.5 (2014): 445. Advanced Placement Source. Web. 16 Feb. 2017.

Summary:
The academic journal discusses the treatments of EB that have and have not been used. In
addition, it calls into questions the ethics of the disease, as no logical treatments and
procedures have been conducted to prolong the lives of children with EB. The article highlights
the fact that the average life span of 5 months and at most, 3 years. This means that they only
have a short time frame to experiment with procedures, but it could expand the lives of many
sufferers if they give it a chance. The article states that Junctional epidermolysis bullosa has an
extremely poor prognosis, with a mean age of death at 5 months old and most died before age
3 years, so they want to find other procedures to have more effective treatments and to
potentially guarantee a longer life span and a more normal life. This source is credible because
it was written by medical doctors in dermatology, which reveals that they have seen patients
with this disease and the aim is to treat it effectively. They have found the common causes of
death were failure to thrive, respiratory failure, and sepsis which is helpful in determining what
to eliminate and how to eliminate death at a young age due to epidermolysis bullosa. In
addition, this academic journal is written for an audience that is interested in this topic because
it is written for the American Journal of Clinical Dermatology. This source is very useful in
describing the ethics of treatments that have not been used before, but make logical sense. The
authors bring up the point on how their main mission is to cause no harm and to save lives, but
they are not doing so by not experimenting with procedures that could potentially lead to a cure
of Epidermolysis Bullosa or lessen the severity of the symptoms that come along with the
disease. I will use this source as a way of discussing innovations that can be make in the
treatment of Epidermolysis Bullosa. In addition, I will discuss how each of these procedures
might be useful in finding a cure and adding onto what the authors say by explaining my point of
view on why these treatments have not been conducted.